Can rasagiline be stopped suddenly? Precautions and risk analysis for patients when discontinuing medication

Rasagiline is a monoamine oxidase B inhibitor (MAO-B inhibitor) used to treat Parkinson's disease. It relieves the motor symptoms of Parkinson's patients by inhibiting the breakdown of dopamine in the brain. Although this drug has good efficacy and tolerability, patients need to exercise caution during use, especially when discontinuing the drug. Sudden discontinuation of rasagiline may carry certain risks and must be done under the guidance of a professional physician.

First of all, rasagiline does not recommend “abrupt discontinuation”. This is because long-term use of the drug can maintain relatively stable dopamine levels. If it is interrupted hastily, it may cause a sudden drop in dopamine levels, which may lead to a sharp worsening of Parkinson's symptoms, including increased tremor, increased stiffness, slow movement and even "freeze". In addition, some patients may experience the so-called "rebound phenomenon" after stopping the drug, that is, the symptoms are more severe than before taking the drug, affecting the quality of life and daily activities.

Secondly, for situations that require discontinuation of medication (such as the occurrence of serious adverse reactions or the need to change treatment regimens), the dosage should be gradually reduced under the guidance of a doctor. Doctors usually adjust the dosage based on the patient's symptom control, disease progression, and other medications to avoid sudden adaptation of the nervous system. At the same time, patients need to be closely observed for new movement disorders or mood changes. If there are any abnormalities, they should seek medical treatment immediately.
Finally, psychological adjustment during drug withdrawal is equally important. Many patients develop anxiety out of fear of worsening symptoms, and this mental stress may in turn aggravate the clinical manifestations of Parkinson's disease. Therefore, family members and medical staff should provide good communication and support, explain to patients the necessity of drug discontinuation, transition plans and alternative therapies, and help them to smoothly go through the drug withdrawal period. To sum up, rasagiline should not be stopped suddenly. If patients need to stop taking it or change treatment plans, they should manage it scientifically under the guidance of professional doctors to ensure medication safety and disease stability.
Reference: https://www.azilect.com/